256 related articles for article (PubMed ID: 21976975)
1. Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity.
Ding B; Wu X; Fan W; Wu Z; Gao J; Zhang W; Ma L; Xiang W; Zhu Q; Liu J; Ding X; Gao S
Int J Nanomedicine; 2011; 6():1991-2005. PubMed ID: 21976975
[TBL] [Abstract][Full Text] [Related]
2. DR5 mAb-conjugated, DTIC-loaded immuno-nanoparticles effectively and specifically kill malignant melanoma cells in vivo.
Ding B; Zhang W; Wu X; Wang J; Xie C; Huang X; Zhan S; Zheng Y; Huang Y; Xu N; Ding X; Gao S
Oncotarget; 2016 Aug; 7(35):57160-57170. PubMed ID: 27494835
[TBL] [Abstract][Full Text] [Related]
3. Targeting nodal in conjunction with dacarbazine induces synergistic anticancer effects in metastatic melanoma.
Hardy KM; Strizzi L; Margaryan NV; Gupta K; Murphy GF; Scolyer RA; Hendrix MJ
Mol Cancer Res; 2015 Apr; 13(4):670-80. PubMed ID: 25767211
[TBL] [Abstract][Full Text] [Related]
4. Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression.
Faião-Flores F; Quincoces Suarez JA; Fruet AC; Maria-Engler SS; Pardi PC; Maria DA
PLoS One; 2015; 10(3):e0118702. PubMed ID: 25742310
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Lillehammer T; Engesaeter BO; Prasmickaite L; Maelandsmo GM; Fodstad O; Engebraaten O
J Gene Med; 2007 Jun; 9(6):440-51. PubMed ID: 17410615
[TBL] [Abstract][Full Text] [Related]
7. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
9. Protocatechuic aldehyde acts synergistically with dacarbazine to augment DNA double-strand breaks and promote apoptosis in cutaneous melanoma cells.
Pei J; Su Z; Zeng X; Zhong Y; Zhang Y; Yang Y; Lu Q; Li J; Deng Y
BMC Complement Med Ther; 2023 Apr; 23(1):111. PubMed ID: 37024907
[TBL] [Abstract][Full Text] [Related]
10. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Huncharek M; Caubet JF; McGarry R
Melanoma Res; 2001 Feb; 11(1):75-81. PubMed ID: 11254118
[TBL] [Abstract][Full Text] [Related]
11. The curcumin analog DM-1 induces apoptotic cell death in melanoma.
Faião-Flores F; Suarez JA; Maria-Engler SS; Soto-Cerrato V; Pérez-Tomás R; Maria DA
Tumour Biol; 2013 Apr; 34(2):1119-29. PubMed ID: 23359272
[TBL] [Abstract][Full Text] [Related]
12. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
13. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.
Xiong W; Guo Z; Zeng B; Wang T; Zeng X; Cao W; Lian D
Front Bioeng Biotechnol; 2022; 10():847901. PubMed ID: 35252156
[TBL] [Abstract][Full Text] [Related]
16. Sonodynamic Therapy Using Dacarbazine-Loaded AuSiO
Esmailzadeh A; Shanei A; Attaran N; Hejazi SH; Hemati S
Ultrasound Med Biol; 2022 Jun; 48(6):1131-1142. PubMed ID: 35307236
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
18. Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M; Shimizu S; Mori E; Kataoka S; Shiokawa Y
Neuro Oncol; 2010 Jul; 12(7):687-700. PubMed ID: 20511188
[TBL] [Abstract][Full Text] [Related]
19. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine.
Thangasamy T; Sittadjody S; Limesand KH; Burd R
Cell Oncol; 2008; 30(5):371-87. PubMed ID: 18791269
[TBL] [Abstract][Full Text] [Related]
20. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
Risberg K; Fodstad O; Andersson Y
J Immunother; 2010 Apr; 33(3):272-8. PubMed ID: 20445347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
